Glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl dipeptidase 4 (DDP-4) inhibitors increase insulin secretion and decrease hyperglucagonemia, thereby lowering hyperglycemia [12–14]. The gene discussed is INS; the disease is Hyperglycemia.